Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Adjuvant Therapy
Interventions: DRUG: Paclitaxel|DRUG: Trastuzumab|DRUG: Docetaxel
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University